Cullinan Therapeutics, Inc.
CGEM · XNASCIK 1789972fmd_0KCBC2KBXDAKJNTGCZKBKF9FYSManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | 0 | 19 | 0 | – | – | – |
| Research and development | 43 | 58 | 92 | 148 | 143 | 187 |
| Total operating expenses | 60 | 87 | 132 | 191 | 197 | 242 |
| Operating income | (60) | (68) | 145 | (191) | (197) | (242) |
| Interest and investment income | 1 | 0 | 7 | 22 | 30 | 22 |
| Other non-operating income (expense) | (0) | (0) | 0 | 0 | (0) | (0) |
| Income before taxes | – | (67) | 151 | (169) | (167) | (220) |
| Income tax expense | – | 0 | 42 | (14) | 0 | 0 |
| Net income from continuing operations | – | (67) | 109 | (155) | (168) | (220) |
| Net income | (52) | (66) | 111 | (153) | (167) | (220) |